Insomnia Disorder - Nonpharmacologic and Pharmacologic Care

Key Points

• CBT-I is the first-line treatment for chronic insomnia and is more effective than sleep hygiene alone.
• Diagnose insomnia from sleep difficulty plus daytime impairment despite adequate sleep opportunity.
• Evaluate for sleep apnea, restless legs, circadian disorder, mood illness, substance use, and medication effects.
• Polysomnography is not routinely needed for uncomplicated insomnia.
• Medication choice should match sleep-onset versus sleep-maintenance difficulty and individual safety risks.
• Avoid combining sedative hypnotics with alcohol, opioids, or other respiratory depressants whenever possible.
• Do not use antipsychotics simply as sleeping pills in primary insomnia.
• A stable wake time and reduction of excessive time in bed are central behavioral targets.

Algorithm

1. Characterize sleep timing, opportunity, latency, awakenings, naps, and daytime impairment.
2. Screen for snoring/apnea, restless legs, circadian mismatch, parasomnias, pain, mood disorders, and substance use.
3. Use a 1- to 2-week sleep diary when useful to clarify patterns.
4. Offer structured CBT-I as first-line therapy.
5. Address comorbid sleep and medical conditions concurrently.
6. If medication is needed, select the lowest-risk agent matched to the predominant insomnia pattern.
7. Reassess next-day impairment, falls, complex sleep behaviors, tolerance, and continued need.
8. Taper chronic sedatives gradually and maintain CBT-I skills to reduce relapse.

Clinical Synopsis & Reasoning

Insomnia disorder is diagnosed from a persistent sleep complaint plus daytime consequences, not from a specific number of hours slept. The patient should have adequate opportunity and circumstances for sleep yet experience difficulty falling asleep, repeated awakenings, early awakening, or nonrestorative sleep with impairment in energy, cognition, mood, work, driving, or quality of life. A sleep history should define bedtime, wake time, naps, variability between workdays and weekends, time in bed, estimated sleep latency, awakenings, snoring, witnessed apneas, gasping, restless legs symptoms, parasomnias, nocturia, pain, hot flashes, shift work, travel, caffeine, alcohol, cannabis, nicotine, and prescription or nonprescription sleep aids.

Insomnia is frequently secondary to or comorbid with depression, anxiety, PTSD, bipolar disorder, chronic pain, obstructive sleep apnea, restless legs syndrome, circadian rhythm disorders, substance use, or medication effects. The presence of another condition does not eliminate the need to treat insomnia directly. Sleep diaries can reveal excessive time in bed, irregular timing, or circadian mismatch. Polysomnography is not routinely required for straightforward chronic insomnia but is indicated when sleep apnea, unusual parasomnia, nocturnal seizures, periodic limb movements, or another sleep disorder is suspected. Before prescribing a sedative, assess fall risk, respiratory disease, opioid or alcohol use, pregnancy, older age, and safety-sensitive occupations.

Treatment Strategy & Disposition

CBT-I is the preferred first-line treatment and is more than generic sleep hygiene. Core components include stimulus control, sleep restriction or sleep compression, cognitive restructuring, relaxation strategies, and a stable wake time. Stimulus control means using the bed primarily for sleep and leaving it temporarily when unable to sleep rather than pairing the bed with prolonged wakeful frustration. Sleep restriction initially limits time in bed to consolidate sleep, then expands it as sleep efficiency improves. This intervention should be modified in patients with conditions such as bipolar disorder, seizure risk, or severe sleepiness when appropriate.

Medication is considered when symptoms remain severe, CBT-I is unavailable or insufficient, or a short-term bridge is clinically justified. Choice should match the sleep problem and patient risk. Options include dual orexin receptor antagonists, low-dose doxepin for sleep maintenance, nonbenzodiazepine receptor agonists, or selected benzodiazepines, with careful attention to next-day impairment, falls, complex sleep behaviors, tolerance, and respiratory depressant combinations. Routine use of sedating antipsychotics is not justified for primary insomnia because metabolic and neurologic harms are disproportionate. Alcohol and cannabis are unreliable sleep treatments and can worsen sleep architecture or dependence. Reassess every hypnotic for ongoing indication and taper chronic sedatives gradually rather than stopping abruptly.

Epidemiology / Risk Factors

• Chronic insomnia is common and frequently coexists with psychiatric, pain, cardiometabolic, and sleep disorders.
• Insomnia can persist after the original precipitating stressor resolves because conditioned arousal and maladaptive sleep behaviors become self-sustaining.
• Older adults are particularly vulnerable to falls and cognitive adverse effects from sedative medications.
• Irregular schedules and shift work can mimic or worsen insomnia through circadian misalignment.

Investigations

Medication Notes

Pharmacology

Prognosis / Complications

• CBT-I has durable benefit and reduces relapse better than relying solely on nightly sedatives.
• Untreated insomnia can worsen mood, cognition, pain perception, driving safety, and quality of life.
• Medication benefit may diminish with tolerance, and discontinuation can cause rebound symptoms if not tapered appropriately.
• Prognosis improves when comorbid sleep apnea, substance use, depression, anxiety, and pain are treated concurrently.

Patient Education / Counseling

• Explain that spending more time in bed can paradoxically worsen chronic insomnia by weakening sleep drive.
• Set a consistent wake time every day, including after a poor night, unless a clinician has advised otherwise.
• Avoid alcohol as a sleep aid because it fragments sleep and increases interaction risk with hypnotics.
• Discuss next-day driving and fall risk before starting sedating medication.
• Seek evaluation for loud snoring, witnessed apneas, gasping, dangerous daytime sleepiness, mania, or parasomnia behaviors.

Notes

The key distinction is between making someone sleepy tonight and treating the process that keeps insomnia chronic. Hypnotics can reduce latency or awakenings, but CBT-I changes conditioned arousal, schedule irregularity, catastrophic beliefs about sleep, and excessive time in bed. For many patients, these are the mechanisms that determine long-term recovery.

When insomnia does not respond, revisit the diagnosis rather than escalating sedatives. Unrecognized sleep apnea, circadian delay, restless legs, mania, substance use, chronic pain, and medication effects are common explanations. Referral to sleep medicine is appropriate for suspected sleep-disordered breathing, parasomnia, movement disorder, diagnostic uncertainty, or persistent symptoms despite well-delivered CBT-I.

References

1. AASM Behavioral and Psychological Treatments for Chronic Insomnia Disorder — Link